The main purpose of this legislation is to improve access to orphan drugs, which are medications developed to treat rare diseases. It aims to enhance the Drug Price Negotiation Program by expanding the criteria for what qualifies as an orphan drug, thereby allowing for better pricing negotiations and ensuring that patients with rare conditions have access to necessary treatments. Key provisions of the legislation include changes to how the time for drug approval is calculated.